1 citations
,
June 2020 in “Annals of the rheumatic diseases” In this study, 93% of patients with inflammatory arthritis remained on the adalimumab biosimilar ABP 501 for 24 weeks after switching from the originator, with some switching back due to adverse reactions or reduced effectiveness.
July 2024 in “Journal of Investigative Dermatology” This study examined the market trends for biologics that have lost patent exclusivity and predicted that drugs like adalimumab, once facing competition, could see price reductions and decreased market share, although the impact on accessibility and total patient use remains unclear.
December 2025 in “Journal of Inflammation Research” This study highlights ongoing inequities in access and outcomes for inflammatory skin diseases in Latin America and emphasizes the need for regional registries, harmonized clinical guidelines, and policy reforms to improve equitable dermatologic care.
November 2023 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in patient care and education.